NetworkNewsWire Editorial Coverage: The potential of cannabis for the treatment of an array of medical conditions is a hot topic, and, while many states in America have legalized the use of marijuana in one form or another, the Food and Drug Administration (FDA) is loath to approve drugs from this source. The FDA has concerns with the consistency of drugs extracted from marijuana, and current Good Manufacturing Practices (GMP) regulations are difficult to implement with naturally-sourced products, dissuading most pharmaceutical companies from pursuing this avenue. A possible solution to the FDA’s concern with quality and consistency lies in the biosynthesis of cannabinoids. Biosynthesis gives manufacturers the ability to produce a high-quality and consistent active ingredient every time, eliminating concerns of crop variability and pesticide contaminants while greatly reducing cost. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (
IMLFF Profile) stands out as a unique biotech drug development company in this regard, positioning it among the ranks of bigger companies like Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a clinical-stage pharmaceutical company developing proprietary synthetic (chemistry-based) cannabinoid treatments for transdermal delivery, and GW Pharmaceuticals plc (NASDAQ: GWPH), which is also at the forefront of pre-clinical research and development of cannabinoids that are extracted from plants. Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED) and Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB) are major suppliers of high-quality, medical-grade marijuana, which is critical for many biotech companies who need a source of plant-based starting materials.
The issue is that plant-based processes (planting, growing, harvesting, extracting and purifying) result in active ingredients at varying concentration levels with inconsistent qualities, including impurities such as pesticides. Companies interested in this approach for their products need to establish vast and high-volume marijuana greenhouse growing operations. This is a huge expense, further compounded by the complex process to produce pharmaceutical grade cannabinoids that meet the GMP requirements for FDA approval. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has taken the inside track in the industry and has just completed the world’s first-ever recorded study that successfully stitched together several key components in the drug development continuum for cannabinoid therapies, including:
- biosynthesizing a cannabinoid;
- packaging the cannabinoid as a nanoparticle;
- formulating the nanoparticles into a novel tissue-specific delivery vehicle;
- and confirming delivery and diffusion into the target tissue.
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
